AHK-Cu (Copper Tripeptide-3) Research Evidence
The AHK-Cu (Copper Tripeptide-3) evidence base: trials, journals, and what the data does not yet show.
Cosmetic Industry vs. Research-Peptide Evidence
Most published evidence on AHK-Cu comes from cosmetic-industry and in-vitro dermal-papilla-cell research, funded largely by cosmetic ingredient suppliers, rather than independent clinical trials. This is a different evidence pathway than pharmaceutical drug development, and claims should be weighed accordingly — a cosmetic ingredient can be legally marketed without FDA drug-style efficacy trials.
Regulatory and Legal Status
AHK-Cu's legal status depends entirely on the form sold. Topical AHK-Cu, used in cosmetic serums and scalp products, is regulated as a cosmetic ingredient and does not require FDA premarket drug approval. Injectable or microneedling-delivered AHK-Cu, sold by research-peptide vendors, is a separate, unapproved research chemical — not approved for human use in that form, and sold RUO. Don't conflate the two: a legally-sold cosmetic serum and an unapproved injectable research vial are regulated completely differently.
References
- The effect of tripeptide-copper complex on human hair growth in vitro · Pyo HK, Yoo HG, Won CH · 2007